文献速递胸部肿瘤

恶性胸膜间皮瘤的放射治疗

Radiotherapy for the treatment of malignant pleural mesothelioma.
PubMed 文献 · Lancet Oncol · 2017-01-01

恶性胸膜间皮瘤预后差,传统认为对放疗抵抗,但近15年调强放疗等高适形技术使全半胸高剂量照射成为可能。前瞻性单臂试验显示,胸膜外全肺切除术后完成高剂量半胸放疗者中位生存可达23.9至39.4个月,且不依赖化疗反应,提示IMRT可能对该亚组有内在获益。这些观察推动了胸膜切除剥脱术后辅助胸膜IMRT及诱导加速半胸IMRT后胸膜外全肺切除等实践转变。

要点

  • 传统认为恶性胸膜间皮瘤对放疗抵抗,但近期证据提示放疗可产生积极结果。
  • 前瞻性单臂试验中,胸膜外全肺切除术后完成高剂量半胸放疗者中位生存达23.9至39.4个月,且不依赖化疗反应。
  • 上述观察推动了胸膜切除剥脱术后辅助胸膜IMRT及诱导加速半胸IMRT后胸膜外全肺切除的实践转变。

核心结论

  • 近期证据提示放疗可对恶性胸膜间皮瘤产生积极结果,高剂量半胸放疗在完成胸膜外全肺切除术后患者中位生存可达23.9至39.4个月且不依赖化疗反应,提示IMRT可能对该亚组有内在获益。

研究设计与样本

  • 本文为综述,聚焦近期关于放疗在恶性胸膜间皮瘤治疗中作用的观察,重点评估高剂量半胸放疗的临床试验结果。

主要发现

  • 前瞻性单臂试验显示,胸膜外全肺切除术后完成高剂量半胸放疗的患者中位生存可达23.9至39.4个月,且不依赖化疗反应。

临床怎么用

  • 上述观察已导致实践改变,包括引入胸膜切除剥脱术后辅助胸膜IMRT,以及开展诱导加速半胸IMRT后胸膜外全肺切除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malignant pleural mesothelioma is an aggressive disease that continues to be associated with poor outcomes. Although, traditionally this disease is considered to be resistant to radiotherapy, more recent evidence suggests that radiotherapy can produce positive outcomes. Over the past 15 years, the development of new, highly conformal radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT), has enabled investigators to optimise the delivery of high-dose radiotherapy to the whole of the hemithorax. Prospective single-arm trials have shown that the median survival of patients who have completed high-dose hemithoracic radiotherapy after extrapleural pneumonectomy could reach 23·9-39·4 months independent of the chemotherapeutic response, suggesting that IMRT could potentially have an intrinsic benefit to this subset of patients. These observations have led to a change in practice, with the introduction of adjuvant pleural IMRT after pleurectomy-decortication and the development of induction-accelerated hemithoracic IMRT followed by extrapleural pneumonectomy. This Review focuses on recent observations on the role of radiotherapy in the treatment of malignant pleural mesothelioma, with particular emphasis on the results of clinical trials that evaluate the role of high-dose hemithoracic radiotherapy.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. de Perrot M, Wu L, Wu M, et al. Radiotherapy for the treatment of malignant pleural mesothelioma. Lancet Oncol. 2017. PMID: 28884702. doi:10.1016/S1470-2045(17)30459-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。